IL6R and obstructive sleep apnea syndrome: OSA patients receiving airways therapy had a median level of soluble IL6R that was 2.8-fold higher than that observed in untreated patients (p = 1.1 × 10−9), a level that was indistinguishable from that of the control group (p = 0.95, Fig. 1b).